Hormonal Regulation of Body Weight Maintenance
12 janvier 2018 mis à jour par: Professor Joachim Spranger, Charite University, Berlin, Germany
The investigators here propose to perform a collaborative clinical research effort including a randomized controlled trial investigating the mechanisms of weight maintenance and their relation to a lifestyle intervention in children, adolescents and adults.
The detailed investigation and analysis of the variability and dynamics of the endocrine circuits responding to a negative energy balance and weight loss will be accompanied and enhanced by specific clinical projects targeting peripheral and central-nervous aspects of hormonal counter-regulation after weight loss.
Mechanisms of endocrine counter-regulation and potential therapeutic approaches will be studied.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
286
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Berlin, Allemagne, 12200
- Charité
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
10 ans à 90 ans (Enfant, Adulte, Adulte plus âgé)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- BMI > 27 kg/m2 (adults)
Exclusion Criteria:
- weight loss of more than 5kg in the last 2 months
- pregnancy, breastfeeding
patients with:
- severe heart failure
- impaired hepatic or renal function
- anaemia
- disturbed coagulation (biopsies will not be taken in those subjects)
- infection, malabsorption
- severe hypertension
- cancer within the last 5 years
- eating disorders or any other psychiatric condition that would interact with the trial intervention
- any other endocrine disorder
- changes of smoking habits or diets within the last 3 months prior to study inclusion
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: placebo
Placebo
|
aucune intervention, seulement un suivi
|
|
Expérimental: lifestyle intervention
After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
|
After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
BMI will be assessed during lifestyle intervention in (1) children and adolescents and (2) adults vs. placebo
Délai: 21 months
|
BMI (kg/m2) will be analyzed after intentional weight loss in two comparable parts of a randomized controlled trial including (1) children and adolescents and (2) adults.
Therefore effects of a multimodal lifestyle intervention will be compared to placebo.
|
21 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Evaluation of leptin during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of leptin at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of leptin during follow up
Délai: 48 months
|
Measurement of leptin during follow up until the 48 months
|
48 months
|
|
Evaluation of catecholamines during follow up
Délai: 48 months
|
Measurement of catecholamines during follow up until the 48 months
|
48 months
|
|
Evaluation of catecholamines during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of catecholamines at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of cortisol during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of cortisol at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of cortisol during follow up
Délai: 48 months
|
Measurement of cortisol during follow up until the 48 months
|
48 months
|
|
Evaluation of glucagon-like peptide 1 (GLP1) during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of GLP1 at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of GLP1 during follow up
Délai: 48 months
|
Measurement of GLP1 during follow up until the 48 months
|
48 months
|
|
Evaluation of glucose-dependent insulinotropic polypeptide (GIP) during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of GIP at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of GIP during follow up
Délai: 48 months
|
Measurement of GIP during follow up until the 48 months
|
48 months
|
|
Evaluation of thyroid hormones during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of thyroid hormones at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of thyroid hormones during follow up
Délai: 48 months
|
Measurement of thyroid hormones during follow up until the 48 months
|
48 months
|
|
Evaluation of insulin during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of insulin at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of insulin during follow up
Délai: 48 months
|
Measurement of insulin during follow up until the 48 months
|
48 months
|
|
Evaluation of insulin-like growth factor 1 (IGF1) during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of IGF1 at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of IGF1 during follow up
Délai: 48 months
|
Measurement of IGF1 during follow up until the 48 months
|
48 months
|
|
Evaluation of natriuretic peptide during lifestyle intervention
Délai: month -3, month 0, month 12, month 18
|
Measurement of natriuretic peptide at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and after additional 6 months follow up
|
month -3, month 0, month 12, month 18
|
|
Evaluation of natriuretic peptide during follow up
Délai: 48 months
|
Measurement of natriuretic peptide during follow up until the 48 months
|
48 months
|
|
Evaluation of blood pressure during lifestyle intervention
Délai: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Measurement of blood pressure at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
Evaluation of free fatty acids (FFAs) during lifestyle intervention
Délai: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Measurement of FFAs at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
Evaluation of respiratory coefficient during lifestyle intervention
Délai: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Measurement of respiratory coefficient at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
Measurement of messenger ribonucleic acid (mRNA) changes in adipose and skeletal muscle before (T-3), after weight loss (T0) and after as well as after 12 months randomized lifestyle intervention (or placebo)
Délai: month -3, month 0, month 12
|
Measurement of systemic and tissue specific changes in adipose tissue and skeletal muscle using RNA sequencing (counts)
|
month -3, month 0, month 12
|
|
Measurement of insulin sensitivity
Délai: month -3, month 0, month 12
|
Measurement of systemic and tissue specific changes in adipose and muscle insulin sensitivity using hyperinsulinemic clamp (mg•kg-1•min-1/(mU•L-1)) before (T-3), after weight loss (T0) and after as well as after 12 months randomized lifestyle intervention (or placebo)
|
month -3, month 0, month 12
|
|
Prediction of body weight regain
Délai: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on long-term course of BMI (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of insulin sensitivity
Délai: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on insulin sensitivity (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of energy expenditure
Délai: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on energy expenditure (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of muscle mass
Délai: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on muscle mass (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
Prediction of fat mass
Délai: month 18, month 48
|
No additional measurement will be done.
However, we will analyse the predictive impact of already measured parameters on fat mass (18 and 48 months) using mathematical models
|
month 18, month 48
|
|
BMI course after a lifestyle intervention in (1) children and adolescents and (2) adults vs. placebo
Délai: month 24, month 36, month 48
|
BMI (kg/m2) after the randomized control trial (RCT) (18 months) will be analyzed up to 48 months.
|
month 24, month 36, month 48
|
|
changes of fatty acids during the intervention
Délai: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Analysis of fatty acids at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
|
changes acylcarnitines
Délai: month -3, month 0
|
Analysis of acylcarnitines at baseline and after 3 months of weight loss
|
month -3, month 0
|
|
changes acylcarnitines
Délai: month 12, month 18, month 24, month 36, month 48
|
Analysis of acylcarnitines after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month 12, month 18, month 24, month 36, month 48
|
|
body composition
Délai: month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Whole body fat mass (kg, %) will be measured at baseline, after 3 months of weight loss, as well as after 12 months randomized lifestyle intervention (or placebo) and and after additional 36 months follow up
|
month -3, month 0, month 12, month 18, month 24, month 36, month 48
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Li L, Soll D, Leupelt V, Spranger J, Mai K. Weight loss-induced improvement of body weight and insulin sensitivity is not amplified by a subsequent 12-month weight maintenance intervention but is predicted by adaption of adipose atrial natriuretic peptide system: 48-month results of a randomized controlled trial. BMC Med. 2022 Jul 28;20(1):238. doi: 10.1186/s12916-022-02435-9.
- Soll D, Gawron J, Pletsch-Borba L, Spranger J, Mai K. Long-term impact of the metabolic status on weight loss-induced health benefits. Nutr Metab (Lond). 2022 Mar 28;19(1):25. doi: 10.1186/s12986-022-00660-w.
- Li L, Spranger L, Stobaus N, Beer F, Decker AM, Wernicke C, Brachs S, Brachs M, Spranger J, Mai K. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss-weight maintenance. Nutr Diabetes. 2021 Oct 5;11(1):31. doi: 10.1038/s41387-021-00174-z.
- Li L, Spranger L, Soll D, Beer F, Brachs M, Spranger J, Mai K. Metabolic impact of weight loss induced reduction of adipose ACE-2 - Potential implication in COVID-19 infections? Metabolism. 2020 Dec;113:154401. doi: 10.1016/j.metabol.2020.154401. Epub 2020 Oct 13.
- Brachs S, Polack J, Brachs M, Jahn-Hofmann K, Elvert R, Pfenninger A, Barenz F, Margerie D, Mai K, Spranger J, Kannt A. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity but Does Not Affect Glucose Tolerance. Diabetes. 2019 Mar;68(3):527-542. doi: 10.2337/db18-0780. Epub 2018 Dec 14.
- Mai K, Li L, Wiegand S, Brachs M, Leupelt V, Ernert A, Kuhnen P, Hubner N, Robinson P, Chen W, Krude H, Spranger J. An Integrated Understanding of the Molecular Mechanisms of How Adipose Tissue Metabolism Affects Long-term Body Weight Maintenance. Diabetes. 2019 Jan;68(1):57-65. doi: 10.2337/db18-0440. Epub 2018 Nov 2.
- Bau AM, Ernert A, Krude H, Wiegand S. Hormonal regulatory mechanisms in obese children and adolescents after previous weight reduction with a lifestyle intervention: maintain - paediatric part - a RCT from 2009-15. BMC Obes. 2016 Jun 10;3:29. doi: 10.1186/s40608-016-0110-8. eCollection 2016.
- Brachs M, Wiegand S, Leupelt V, Ernert A, Kintscher U, Jumpertz von Schwarzenberg R, Decker AM, Bobbert T, Hubner N, Chen W, Krude H, Spranger J, Mai K. ANP system activity predicts variability of fat mass reduction and insulin sensitivity during weight loss. Metabolism. 2016 Jun;65(6):935-43. doi: 10.1016/j.metabol.2016.03.013. Epub 2016 Apr 7.
- Weygandt M, Mai K, Dommes E, Ritter K, Leupelt V, Spranger J, Haynes JD. Impulse control in the dorsolateral prefrontal cortex counteracts post-diet weight regain in obesity. Neuroimage. 2015 Apr 1;109:318-27. doi: 10.1016/j.neuroimage.2014.12.073. Epub 2015 Jan 7.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 janvier 2010
Achèvement primaire (Réel)
1 décembre 2015
Achèvement de l'étude (Réel)
1 janvier 2016
Dates d'inscription aux études
Première soumission
17 février 2009
Première soumission répondant aux critères de contrôle qualité
24 février 2009
Première publication (Estimation)
25 février 2009
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
17 janvier 2018
Dernière mise à jour soumise répondant aux critères de contrôle qualité
12 janvier 2018
Dernière vérification
1 janvier 2018
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EA2/017/09
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .